SeriACL Device ACL Reconstruction
DeviceLong-term Bioresorbable ACL Scaffold
NCT Number: NCT00775892
A multi-center single-arm clinical trial is being conducted to evaluate SeriACL device safety and performance during total anterior cruciate ligament (ACL) reconstruction.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1 / Phase 2
Dr. Pierer Sanatorium, Salzburg, Austria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Major Inclusion Criteria:
Major Exclusion Criteria:
Long-term Bioresorbable ACL Scaffold
Time frame: 12 months
Time frame: 12 months
Time frame: 12 months
Serica Technologies, Inc.
Industry
A Multi-Center Open Label Study to Evaluate the SeriACL™ Device (Gen IB) for Primary Anterior Cruciate Ligament Repair
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07532980
Anterior Cruciate Ligament Reconstruction, Knee Injuries
Konya, Karatay, Turkey (Türkiye)
View Trial DetailsNCT07601529
Anterior Cruciate Ligament Reconstruction
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07540715
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Reconstruction
Konya, Turkey (Türkiye)
View Trial DetailsNCT05136352
Anesthesia, Anterior Cruciate Ligament Reconstruction
Toulouse, France
View Trial Details